Navigation Links
Royalty Pharma Announces that Alexander von Perfall Joins Management Team

NEW YORK, Dec. 7 /PRNewswire/ -- Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.


Alexander has 13 years of cross-border management advisory, strategic planning and principal investment experience, most recently as co-founder and Chief Network Officer of XTF, a start-up Exchange Traded Funds Ratings Agency. He previously advised the International Finance Corporation/World Bank Group on the syndication of media sector private equity investments. Alexander started his career with Bertelsmann AG where he held various management positions, culminating with a position as Director of Business Development where he initiated and oversaw investments in a number of early stage media and entertainment ventures. Alexander attended the Hoschchule St. Gallen in Switzerland before obtaining a BA in Politics from the University of San Francisco and an MBA from the New York University - Stern School of Business.

"The addition of Alexander to our management team adds an important element of investor relationship management," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "Alexander will play a key role in Royalty Pharma's efforts to enhance its investor and key stakeholder strategy and communication, including acting as a liaison between Royalty Pharma's management team and equity and debt investors, the analyst community and media representatives."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property - principally royalty interests in marketed and late stage biopharmaceutical products with approximately $6 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including Abbott's Humira®, J&J/Merck's Remicade®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Gilead's Emtriva®, Truvada® and Atripla®, and Celgene's Thalomid®. Royalty Pharma has a thirteen year history of providing value to holders of royalty interests, including its $700 million purchase of the Lyrica® royalty from Northwestern University, its $650 million purchase of the Remicade® royalty from New York University, its $700 million purchase of the Humira® royalty from AstraZeneca plc following its acquisition of Cambridge Antibody Technology, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen® and Neulasta® for over $400 million. For more information, go to

For additional information, please contact:
Pablo Legorreta                                Alexander v. Perfall
Chief Executive Officer                        VP, Investor Relations
+ 1 (212) 883-2288                             + 1 (212) 883-2298         

More information on Royalty Pharma is available at

SOURCE Royalty Pharma

SOURCE Royalty Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
2. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
3. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting
8. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
9. Amber Pharmacy Earns Accreditation From ACHC
10. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
11. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Trovagene, Inc. (NASDAQ: TROV ... that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled ... Annual Piper Jaffray Healthcare Conference. th ... York Palace Hotel in New York ... EST. Mr. Schuh will be available for one-on-one meetings ...
(Date:11/25/2015)... Nov. 25, 2015 USP 800 applies ... preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, physician ... The chapter also covers all entities which store, ... hospitals, other healthcare institutions, patient treatment clinics, physicians, ... --> --> What is the ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s ... learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions ... 65 years, Brillianteen has been a treasured tradition for numerous families in the ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):